{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:23:31Z","timestamp":1790447011188,"version":"4.1.0"},"reference-count":46,"publisher":"Cambridge University Press (CUP)","issue":"2","license":[{"start":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T00:00:00Z","timestamp":1639353600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can. J. Neurol. Sci."],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>ABSTRACT:<\/jats:title><jats:p>The complement system is a tightly controlled signaling network that plays a role in innate immune surveillance. However, abnormal signaling through this pathway contributes to tissue damage in several inflammatory, autoimmune, and degenerative diseases. Myasthenia gravis (MG) and neuromyelitis optica spectrum disorders (NMOSD) have complement dysfunction at the core of pathogenesis, providing a strong rationale for therapeutic targeting of complement components. The purpose of this paper is to briefly review the role of complement activation in the pathogenesis of MG and NMOSD, to discuss the rationale and evidence for complement inhibition as a method to manage these diseases, and to provide a Canadian perspective on the use of complement inhibition therapy through real-world cases of MG and NMOSD.<\/jats:p>","DOI":"10.1017\/cjn.2021.508","type":"journal-article","created":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T09:15:09Z","timestamp":1639386909000},"page":"165-173","source":"Crossref","is-referenced-by-count":13,"title":["Complement Inhibition in Myasthenia Gravis and Neuromyelitis Optica Spectrum Disorder"],"prefix":"10.1017","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5985-3022","authenticated-orcid":false,"given":"Dubravka","family":"Dodig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Genge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Selchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1255-9701","authenticated-orcid":false,"given":"Mark S.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2021,12,13]]},"reference":[{"key":"S0317167121005084_ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00538"},{"key":"S0317167121005084_ref19","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awf151"},{"key":"S0317167121005084_ref26","unstructured":"26. Canadian Agency for Drugs and Technology in Health. CADTH Canadian Drug Expert Committee Recommendation (Final) Eculizumab (Soliris - Alexion Pharma Canada Corp.). Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health; 2020. Available at: https:\/\/www.cadth.ca\/sites\/default\/files\/cdr\/complete\/SR0605%20Soliris%20MG%20-%20CDEC%20Final%20Recommendation%20October%2021%2C%202020_for%20posting.pdf."},{"key":"S0317167121005084_ref31","unstructured":"31. Pharmacoeconomic Report: Eculizumab (Soliris): Alexion Pharma Canada Corporation: Indication: Adult patients with generalized Myasthenia Gravis. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK567413\/."},{"key":"S0317167121005084_ref35","unstructured":"35. PNH National Service Leeds & London. Meningococcal infection and Eculizumab\/Complement Inhibitors. PNH National Service Leeds; 2021. Available at: http:\/\/www.pnhleeds.co.uk\/professionals\/meningococcal-infection-and-eculizumab\/."},{"key":"S0317167121005084_ref42","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13495"},{"key":"S0317167121005084_ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.03.002"},{"key":"S0317167121005084_ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0079-y"},{"key":"S0317167121005084_ref41","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00059-X"},{"key":"S0317167121005084_ref44","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.556104"},{"key":"S0317167121005084_ref2","first-page":"43","article-title":"Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review","volume":"268","author":"Chamberlain","year":"2021","journal-title":"J Neurol"},{"key":"S0317167121005084_ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-015-0387-9"},{"key":"S0317167121005084_ref4","volume-title":"Immunobiology: the immune system in health and disease","author":"Janeway","year":"2001"},{"key":"S0317167121005084_ref7","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13522"},{"key":"S0317167121005084_ref36","unstructured":"36. Haut Conseil de la sant\u00e9 publique. Personnes trait\u00e9es par Soliris\u00ae : actualisation des recommandations de vaccination et d\u2019antibioprophylaxie. Paris, France: Haut Conseil de la sant\u00e9 publique; 2021. Available at: http:\/\/www.hcsp.fr\/Explore.cgi\/avisrapportsdomaine?clefr=447."},{"key":"S0317167121005084_ref39","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16078"},{"key":"S0317167121005084_ref11","unstructured":"11. ProductMonograph PrSOLIRIS\u00ae (eculizumab) [Internet]. Zurich, Switzerland: AlexionPharma GmbH; 2009 [updated 2021 Mar 25; cited 2021 Jul 7]. Available at: https:\/\/alexion.com\/-\/media\/alexion_comredesign\/documents\/canada\/soliris-product-monograph_english_approved_25mar2021.pdf."},{"key":"S0317167121005084_ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30369-1"},{"key":"S0317167121005084_ref24","first-page":"77","article-title":"Satralizumab: first approval","volume":"80","author":"Heo","year":"2020","journal-title":"Drugs"},{"key":"S0317167121005084_ref30","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30363-0"},{"key":"S0317167121005084_ref32","unstructured":"32. Black, C. Assessing the potential impact of recommendations made through the CADTH Common Drug Review (CDR) program. Ottawa, Canada: Canadian Agency for Drugs and Technology in Health; 2019. Available at: https:\/\/cadth.ca\/sites\/default\/files\/symp-2019\/presentations\/april15-2019\/B5-presentation-cblack.pdf."},{"key":"S0317167121005084_ref28","first-page":"95","article-title":"Myasthenia gravis appearing after thymectomy heralding recurrent thymoma","volume":"119","author":"Beckers","year":"2019","journal-title":"Acta Chir Belg"},{"key":"S0317167121005084_ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900866"},{"key":"S0317167121005084_ref34","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6627e1"},{"key":"S0317167121005084_ref22","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26049"},{"key":"S0317167121005084_ref38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127005"},{"key":"S0317167121005084_ref18","doi-asserted-by":"publisher","DOI":"10.1177\/1352458515571446"},{"key":"S0317167121005084_ref8","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.916424"},{"key":"S0317167121005084_ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4146-5"},{"key":"S0317167121005084_ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01370-4"},{"key":"S0317167121005084_ref13","first-page":"2654","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"142","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"key":"S0317167121005084_ref37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0241989"},{"key":"S0317167121005084_ref9","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011124"},{"key":"S0317167121005084_ref46","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.1637"},{"key":"S0317167121005084_ref3","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4657"},{"key":"S0317167121005084_ref25","unstructured":"25. Product Monograph PrENSPRYNG (satralizumab). Mississauga, Canada: Hoffmann-La Roche Limited; 2020. Available at: https:\/\/www.rochecanada.com\/content\/dam\/rochexx\/roche-ca\/products\/ConsumerInformation\/MonographsandPublicAdvisories\/Enspryng\/Enspryng_PM_E.pdf."},{"key":"S0317167121005084_ref40","unstructured":"40. Banerjee, A , Adcock, L. Rituximab for the treatment of myasthenia gravis: a review of clinical effectiveness, cost-effectiveness, and guidelines. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK537803\/."},{"key":"S0317167121005084_ref14","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011207"},{"key":"S0317167121005084_ref43","doi-asserted-by":"publisher","DOI":"10.3109\/08916930903518107"},{"key":"S0317167121005084_ref45","unstructured":"45. Canadian Agency for Drugs and Technology in Health. CADTH Canadian Drug Expert Committee Recommendation (Final) Eculizumab (Soliris - Alexion Pharma Canada Corp.). Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health; 2020. Available at: https:\/\/www.cadth.ca\/sites\/default\/files\/cdr\/complete\/SR0640%20Soliris%20-%20CDEC%20Final%20Recommendation%20August%2024%2C%202020%20for%20posting.pdf."},{"key":"S0317167121005084_ref33","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15790"},{"key":"S0317167121005084_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2018.01.011"},{"key":"S0317167121005084_ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00501"},{"key":"S0317167121005084_ref29","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-2-44"},{"key":"S0317167121005084_ref27","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2007.3.3.158"},{"key":"S0317167121005084_ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00262"}],"container-title":["Canadian Journal of Neurological Sciences \/ Journal Canadien des Sciences Neurologiques"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0317167121005084","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,23]],"date-time":"2023-04-23T23:46:08Z","timestamp":1682293568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0317167121005084\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,13]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0317167121005084"],"URL":"https:\/\/doi.org\/10.1017\/cjn.2021.508","relation":{},"ISSN":["0317-1671","2057-0155"],"issn-type":[{"value":"0317-1671","type":"print"},{"value":"2057-0155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,13]]}}}